GlaxoSmithKline and Pfizer combine HIV-drug business

Law Professor Kevin Outterson, director of the Health Law Program, says big pharma giants GlaxoSmithKline and Pfizer combining their HIV-drug business should be good for the companies and for patients around the globe.

“The joint venture will allow GSK and Pfizer to coordinate antiretroviral-drug research, which will both lower R&D costs and reduce competition between the companies. 

“Given the global importance of this drug category, and Glaxo CEO Andrew Witty’s recent comments on global access to drugs, I hope the joint venture will issue a clear statement on affordable access to ARVs across the entire world.”

Contact Kevin Outterson, 617-353-3103,

Post a Comment

Your email address is never shared. Required fields are marked *